ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
ARA-290 (Erythropoietin-derived tissue-protective peptide) is researched primarily for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes. The only EPO-derived peptide that completely decouples tissue protection from red blood cell production — providing nerve regeneration without any hematologic effects. It belongs to the Innate repair receptor agonist, anti-inflammatory peptide category of compounds.
What Is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO).
The only EPO-derived peptide that completely decouples tissue protection from red blood cell production — providing nerve regeneration without any hematologic effects. It has attracted significant research interest for its potential effects on neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
How Does ARA-290 Produce These Benefits?
Selectively activates the innate repair receptor (IRR), a CD131/EPOR heterodimer, triggering anti-inflammatory and tissue-protective signaling without any effect on red blood cell production. Suppresses microglia activation and pro-inflammatory cytokine release. Dose-dependently reduces neuropathic pain through central inflammation suppression.
This multi-pathway activity is why ARA-290 shows potential across several different applications rather than being limited to a single use case.
Can ARA-290 Help With Neuropathic Pain Relief?
Research suggests ARA-290 may support neuropathic pain relief through its innate repair receptor agonist, anti-inflammatory peptide activity. Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
Protocols targeting neuropathic pain relief typically use 2-4 mg daily administered once daily for 28 days typical; 8-16 weeks for extended response.
Can ARA-290 Help With Inflammation Reduction?
Research suggests ARA-290 may support inflammation reduction through its innate repair receptor agonist, anti-inflammatory peptide activity. Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
Protocols targeting inflammation reduction typically use 2-4 mg daily administered once daily for 28 days typical; 8-16 weeks for extended response.
Can ARA-290 Help With Nerve Fiber Regeneration?
Research suggests ARA-290 may support nerve fiber regeneration through its innate repair receptor agonist, anti-inflammatory peptide activity. Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
Protocols targeting nerve fiber regeneration typically use 2-4 mg daily administered once daily for 28 days typical; 8-16 weeks for extended response.
Can ARA-290 Help With Improved Autonomic Function?
Research suggests ARA-290 may support improved autonomic function through its innate repair receptor agonist, anti-inflammatory peptide activity. Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
Protocols targeting improved autonomic function typically use 2-4 mg daily administered once daily for 28 days typical; 8-16 weeks for extended response.
Can ARA-290 Help With Metabolic Control In Diabetes?
Research suggests ARA-290 may support metabolic control in diabetes through its innate repair receptor agonist, anti-inflammatory peptide activity. Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
Protocols targeting metabolic control in diabetes typically use 2-4 mg daily administered once daily for 28 days typical; 8-16 weeks for extended response.
Can Stacking Enhance ARA-290 Benefits?
Synergizes with BPC-157 for comprehensive tissue repair — ARA-290 handles neuropathic and inflammatory pathways while BPC-157 targets connective tissue and gut healing.
See our ARA-290 stacking guide for detailed combination protocols.
What Is the Bottom Line on ARA-290 Benefits?
ARA-290 is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes. The evidence base includes: Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
ARA-290 is investigational. underwent phase ii clinical trials. not fda-approved. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- ARA-290 Research
- BPC-157 Complete Guide
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.